| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US6310094 | BAXTER HLTHCARE | Ready-to-use esmolol solution |
Jan, 2021
(3 years ago) | |
| US6528540 | BAXTER HLTHCARE | Esmolol formulation |
Jan, 2021
(3 years ago) | |
|
US6310094 (Pediatric) | BAXTER HLTHCARE | Ready-to-use esmolol solution |
Jul, 2021
(2 years ago) | |
|
US6528540 (Pediatric) | BAXTER HLTHCARE | Esmolol formulation |
Jul, 2021
(2 years ago) | |
Brevibloc Double Strength In Plastic Container is owned by Baxter Hlthcare.
Brevibloc Double Strength In Plastic Container contains Esmolol Hydrochloride.
Brevibloc Double Strength In Plastic Container has a total of 4 drug patents out of which 4 drug patents have expired.
Expired drug patents of Brevibloc Double Strength In Plastic Container are:
- US6310094
- US6528540
- US6310094*PED
- US6528540*PED
Brevibloc Double Strength In Plastic Container was authorised for market use on 15 August, 1988.
Brevibloc Double Strength In Plastic Container is available in injectable;injection dosage forms.
The generics of Brevibloc Double Strength In Plastic Container are possible to be released after 12 July, 2021.
Drugs and Companies using ESMOLOL HYDROCHLORIDE ingredient
Market Authorisation Date: 15 August, 1988
Treatment: NA
Dosage: INJECTABLE;INJECTION
BREVIBLOC DOUBLE STRENGTH IN PLASTIC CONTAINER family patents
